Clinical Trial Update: Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating eculizumab for subclinical acute antibody-mediated rejection in kidney transplantation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection
• Kidney Allograft Rejection

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation | Phase 1, Phase 2 | Status: WITHDRAWN